Hepatocellular carcinoma: Difference between revisions
(Text replacement - "* " to "*") |
|||
| Line 12: | Line 12: | ||
*[[Budd-Chiari syndrome]] | *[[Budd-Chiari syndrome]] | ||
==Evaluation== | ==Evaluation== | ||
*LFT, CBC, | *LFT, CBC, BMP, GGT | ||
*Ultrasound | *Ultrasound | ||
*Initial CT and MRI nonemergently | |||
*Biopsy | *Biopsy | ||
*Surveillance with alfa-fetoprotein (AFP) in combination with US<ref>Bialecki ES and Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005; 7(1): 26–34.</ref> | |||
==Management== | ==Management== | ||
Revision as of 17:24, 13 October 2018
Background
- most common form of liver cancer
Clinical Features
- Risk factors include:
- Hepatitis B or C
- toxins (alcohol or aflatoxin)
- Metabolic conditions (hemochromatosis, alpha 1-antitrypsin deficiency, non-alcoholic fatty liver disease)
Differential Diagnosis
- Cirrhosis
- Hepatitis
- Budd-Chiari syndrome
Evaluation
- LFT, CBC, BMP, GGT
- Ultrasound
- Initial CT and MRI nonemergently
- Biopsy
- Surveillance with alfa-fetoprotein (AFP) in combination with US[1]
Management
Disposition
See Also
External Links
References
- ↑ Bialecki ES and Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005; 7(1): 26–34.